Sunshine Heart Announces Company Name Change to CHF Solutions, Inc. and New NASDAQ Ticker Symbol to Reflect New Commercial Focus
"We are pleased to align our corporate name and identity with our new commercial focus," said
In conjunction with the name change, the company's ticker symbol listed on the
NASDAQ will change from SSH to CHFS, which is expected to be effective
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The company's commercial product, the Aquadex system, is indicated for temporary (up to
eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's ticker symbol and events or
developments that we expect or anticipate will occur in the future. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
For further information, please contact:Claudia Napal Drayton Chief Financial OfficerCHF Solutions, Inc. T: +1-952-345-4205 Investor RelationsCHF Solutions, Inc. ir@chf-solutions.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source:
News Provided by Acquire Media